scispace - formally typeset
R

Rajesh Agarwal

Researcher at University of Montana

Publications -  483
Citations -  32284

Rajesh Agarwal is an academic researcher from University of Montana. The author has contributed to research in topics: Silibinin & Apoptosis. The author has an hindex of 92, co-authored 416 publications receiving 29843 citations. Previous affiliations of Rajesh Agarwal include University of Lucknow & Anschutz Medical Campus.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Green Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma Cells

Nihal Ahmad, +4 more
- 17 Dec 1997 - 
TL;DR: Green tea may protect against cancer by causing cell cycle arrest and inducing apoptosis, and needs to be evaluated in human trials.
Journal ArticleDOI

Multitargeted therapy of cancer by silymarin.

Kumaraguruparan Ramasamy, +1 more
- 08 Oct 2008 - 
TL;DR: The protective effects of silymarin and its major active constituent, silibinin, studied in various tissues, suggest a clinical application in cancer patients as an adjunct to established therapies, to prevent or reduce chemotherapy as well as radiotherapy-induced toxicity.
Journal ArticleDOI

Protective Effects of Silymarin Against Photocarcinogenesis in a Mouse Skin Model

Santosh K. Katiyar, +3 more
- 16 Apr 1997 - 
TL;DR: Silymarin can provide substantial protection against different stages of UVB-induced carcinogenesis, possibly via its strong antioxidant properties.
Journal Article

Silibinin Strongly Synergizes Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth Inhibition, G2-M Arrest, and Apoptosis

Anil K. Tyagi, +4 more
- 01 Nov 2002 - 
TL;DR: Findings suggest a need for in vivo studies with this combination of silibinin and doxorubicin against prostate cancer, which is limited because of high systemic toxicity, and might be relevant for a clinical application in prostate cancer patients.